Abstract Library

#1684 An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)

Introduction: In ELECT, LAN 120mg every 4 weeks significantly reduced octreotide rescue therapy use for symptomatic CS control vs placebo (PBO).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Duchateau L

Authors: Duchateau L, Lescrauwaet B, Blot K, Liyanage N, Ray D,

Keywords: SSA, carcinoid, symptoms,

#1475 Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data

Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Dromain C

Authors: Caplin M, Pavel M, Ruszniewski P, Liyanage N, Massien C,

Keywords: TGR, PFS,